摘要
目的观察万古霉素(方刻林)治疗呼吸重症监护室(RICU)下呼吸道耐甲氧西林葡萄球菌(MRS)感染的临床疗效及安全性。方法将2001年10月～2003年5月间我院RICU的MRS感染患者随机分为两组,在常规治疗的基础上,治疗组18例,采用方刻林05g,静脉滴注,3次/d;对照组17例,给予万古霉素05g,静脉滴注,3次/d,两组疗程为7～14d。结果方刻林组治愈率为611%,有效率为944%,细菌清除率为778%;万古霉素组治愈率为647%,有效率为941%,细菌清除率为824%,两组比较差异无显著性。结论方刻林与万古霉素的临床疗效差异无显著性,方刻林治疗下呼吸道MRS感染疗效确切,使用安全。
OBJECTIVE To observe the efficacy and safety of vancomycin in treatment of lower respiratory tract infection with MRS in RICU patients. METHODS Thirty five patients were randomly divided into two groups. Patients were treated with US made vancomycin 0 5g, iv gtt, q8h, for 7 14 days in therapeutic group (n=18), and Republic of Korea made vancomycin (Vancocin) 0 5g, iv gtt q8h in control one(n=17). RESULTS In therapeutic group,the cure rate was 61 1%, the effective rate was 94 4%, and the bacteria eradication rate was 77 8%. In control one,the above three rates were 64 7%, 94 1%, and 82 4%, respectively. There was no statistically significant difference between the two groups. CONCLUSIONS Vancomycin is effective and safe in the treatment of lower respiratory tract infection with MRS.
出处
《中华医院感染学杂志》
CAS
CSCD
2004年第12期1403-1405,共3页
Chinese Journal of Nosocomiology
关键词
万古霉素
下呼吸道感染
MRS
Vancomycin
Lower respiratory tract infection
MRS
